Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?
With the introduction of more effective novel therapies, the prognosis of multiple myeloma (MM) has improved significantly over the past decade, resulting with a significant proportion of patients achieving durable remissions that may reach even more than 10 years. Several studies demonstrated that...
Main Authors: | Guldane Cengiz Seval, Meral Beksac |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.800711/full |
Similar Items
-
The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
by: Rose Turner, et al.
Published: (2022-05-01) -
Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML
by: Alexander D. Heini, et al.
Published: (2021-06-01) -
Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
by: Selina Bühler, et al.
Published: (2023-01-01) -
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
by: Jin Wang, et al.
Published: (2022-08-01) -
Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: A qualitative analysis
by: Owais Mian, et al.
Published: (2023-01-01)